收稿日期: 2020-04-20
网络出版日期: 2020-08-06
基金资助
北大医学交叉研究种子基金-中央高校基本科研业务费(BMU2020MX002)
徐涛 , 韩敬丽 , 姚伟娟 . 雄激素剥夺治疗相关心血管疾病的机制与临床对策[J]. 北京大学学报（医学版）, 2020 , 52(4) : 607 -609 . DOI: 10.19723/j.issn.1671-167X.2020.04.001
| [1] | Gupta D, Lee Chuy K, Yang J C, et al. Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate cancer[J]. J Oncol Pract, 2018,14(10):580-587. |
| [2] | Farrell SO, Garmo H, Holmberg L, et al. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer[J]. J Clin Oncol, 2015,33(11):1243-1251. |
| [3] | Conteduca V, Lorenzo GD, Tartarone A, et al. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: An unresolved controversy[J]. Crit Rev Oncol Hematol, 2013,86(1):42-51. |
| [4] | Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer[J]. J Clin Oncol, 2006,24(27):4448-4456. |
| [5] | Nanda A, Chen MH, Braccioforte MH, et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction[J]. JAMA, 2009,302(8):866-873. |
| [6] | Keating NL, O’Malley AJ, Freedland SJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy: Observational study of veterans with prostate cancer[J]. J Natl Cancer Inst, 2010,102(1):39-46. |
| [7] | Zhao J, Zhu S, Sun L, et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: A meta-analysis of population-based observational studies[J]. PLoS One, 2014,9(9):e107516. |
| [8] | Bosco C, Bosnyak Z, Malmberg A, et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: A meta-analysis[J]. Eur Urol, 2015,68(3):386-396. |
| [9] | Meng F, Zhu S, Zhao J, et al. Stroke related to androgen deprivation therapy for prostate cancer: A meta-analysis and systematic review[J]. BMC Cancer, 2016,16(1):180. |
| [10] | Elagizi A, K?hler TS, Lavie CJ. Testosterone and cardiovascular health[J]. Mayo Clin Proc, 2018,93(1):83-100. |
| [11] | Clinton TN, Woldu SL, Raj GV. Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer[J]. Expert Opin Pharmacother, 2017,18(8):825-832. |
| [12] | Albertsen PC, Klotz L, Tombal B, et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist[J]. Eur Urol, 2014,65(3):565-573. |
| [13] | Margel D, Peer A, Ber Y, et al. Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease[J]. J Urol, 2019,202(6):1199-1208. |
| [14] | A trial comparing cardiovascular safety of degarelix versus leuprolide in patients with advanced prostate cancer and cardiovascular disease(PRONOUNCE)[Z/OL]. (2016-01-26)[2020-04-06]. https://clinicaltrials.gov/ct2/show/NCT02663908?term=NCT02663908&draw=2&rank=1. |
| [15] | Cone EB, Marchese M, Reese S, et al. Lower odds of cardiac events for gonadotrophin-releasing hormone antagonists versus agonists[J/OL]. BJU Int, 3(2020-03-30)[2020-04-10]. https://pubmed.ncbi.nlm.nih.gov/32232935/?from_single_result=Lower+Odds+of+Cardiac+Events+for+Gonadotropic+Releasing+Hormone+Antagonists+versus+Agonists&expanded_search_query=Lower+Odds+of+Cardiac+Events+for+Gonadotropic+Releasing+Hormone+Antagonists+versus+Agonists. |
| [16] | Bubley GJ. Is the flare phenomenon clinically significant?[J]. Urology, 2001,58(2):5-9. |
| [17] | Knutsson A, Hsiung S, Celik S, et al. Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE-/- mice[J]. Sci Rep, 2016,6(1):26220. |
| [18] | Libby P. Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis[J]. J Lipid Res, 2009,50(Suppl):352-357. |
| [19] | Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group phase Ⅲ study in patients with prostate cancer[J]. BJU Int, 2008,102(11):1531-1538. |
| [20] | Zareba P, Duivenvoorden W, Leong DP, et al. Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?[J]. Ther Adv Urol, 2016,8(2):118-129. |
| [21] | Wang Q, Zhou J, Yao W, et al. Follicle-stimulating hormone is responsible for androgen deprivation therapy associated atherosclerosis by exaggerating endothelial inflammation[J]. Eur Urol, 2019,18(Suppl 1):e72. |
| [22] | Bhatia N, Santos M, Jones LW, et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer[J]. Circulation, 2016,133(5):537-541. |
/
| 〈 |
|
〉 |
